Journal of Thyroid Cancer invites high quality submissions that advance thyroid cancer diagnosis, treatment, and survivorship care. We welcome original research, systematic reviews, clinical trials, and translational studies that improve outcomes for patients with thyroid malignancies.

Our editorial focus prioritizes rigorous study design, transparent reporting, and actionable insights for endocrine oncology practice.

• Papillary, follicular, medullary, and anaplastic thyroid carcinoma
• Molecular diagnostics, mutation profiling, and risk stratification
• Ultrasound, imaging, and thyroid nodule evaluation
• Fine needle aspiration cytology and Bethesda classification
• Surgical oncology and lymph node management
• Radioactive iodine therapy and response assessment
• Targeted therapies, immunotherapy, and systemic treatments
• Endocrine outcomes, TSH suppression, and long term follow up
• Recurrence surveillance and biomarkers such as thyroglobulin
• Quality of life, survivorship, and patient reported outcomes
• Clinical guidelines, policy updates, and multidisciplinary care
• Pediatric and hereditary thyroid cancer syndromes

• Clinical trial reports and interim analyses
• Case series with rigorous diagnostic criteria
• Practice or policy briefs grounded in evidence
• Technical notes on surgical or imaging methods

Successful submissions present a clear clinical question, robust diagnostic methodology, and transparent reporting of outcomes. We value studies that connect molecular or imaging findings to clinical decision making.

Authors should document staging, risk stratification, and treatment protocols to support reproducibility and guideline relevance.

• Clear inclusion and exclusion criteria with staging detail
• Validated biomarkers or imaging criteria
• Appropriate statistical analysis and confounder control
• Interpretation aligned with clinical practice implications

Submissions undergo editorial screening for scope fit, methodological rigor, and reporting completeness. Qualified manuscripts move to single blind peer review with subject matter experts.

JTC operates under an open access model to ensure thyroid cancer evidence is discoverable and reusable. APCs are applied after acceptance and support peer review, production, and archiving services.

Membership options and affordable APC waivers are available for eligible authors. Contact the editorial office at [email protected] for guidance.

• Scope fit confirmed for thyroid oncology
• Staging and risk stratification reported
• Data availability statement included
• Ethics approvals and patient consent described
• Cover letter explains novelty and clinical impact
• Report thyroid cancer subtype (papillary, follicular, medullary, anaplastic) and histologic variant.
• Include AJCC staging and ATA risk stratification details.
• Describe ultrasound features using TI-RADS or equivalent scoring.
• Report cytology classification using the Bethesda system.
• Provide tumor size, multifocality, and extrathyroidal extension data.
• Describe lymph node assessment methods and dissection extent.
• Report surgical approach and margin status (R0/R1/R2).
• Include postoperative thyroglobulin levels and antibody status.
• Specify radioactive iodine dose, preparation method, and response criteria.
• Define recurrence, persistence, and follow up intervals clearly.
• Describe imaging modalities used for surveillance and response assessment.
• Report complication rates such as hypocalcemia or recurrent laryngeal nerve injury.
• Provide survival outcomes and event definitions (DFS, OS, PFS).
• Include molecular profiling methods and mutation panels used.
• Report BRAF, RAS, RET, TERT, and other driver alterations when tested.
• Clarify indications for targeted therapies and response metrics.
• Describe criteria for RAI refractory disease.
• Include endocrine outcomes such as TSH suppression targets and dosing.
• Report quality of life or patient reported outcomes when available.
• Document consent procedures and ethics approvals for clinical studies.
• Describe inclusion/exclusion criteria and referral pathways.
• Provide details on family history or MEN2 screening when relevant.
• Clarify pathology review standards and interobserver agreement.
• Include reporting of vascular invasion or capsular invasion.
• Provide data on tumor microenvironment markers or immune profiling.
• Report use of RECIST or other response criteria for systemic therapy.
• Include trial registration identifiers for prospective studies.
• Describe statistical power calculations or sample size justification.
• Report handling of missing data and sensitivity analyses.
• Provide data availability statements and repository access details.
• Clarify whether imaging or pathology data are shareable and how.
• Describe multidisciplinary team involvement in treatment planning.
• Report adherence to guideline recommendations or deviations.
• Provide stratified outcomes by risk group or stage.
• Document long term adverse events or endocrine complications.
• Include details on ablative versus adjuvant RAI strategies.
• Report use of PET/CT or advanced imaging and rationale.
• Describe histopathologic criteria for aggressive variants.
• Provide local or regional recurrence management details.
• Clarify timing between diagnosis, surgery, and adjuvant therapy.
• Report preoperative vocal cord assessment and laryngeal nerve monitoring details.
• Include postoperative calcium management protocols and outcomes.
• Describe tumor growth patterns and variant classification criteria.
• Report detailed lymph node mapping and nodal yield metrics.
• Include timing and criteria for completion thyroidectomy when applicable.
• Provide details on active surveillance protocols for low risk disease.
• Report use of minimally invasive or robotic surgical approaches.
• Clarify criteria for lobectomy versus total thyroidectomy.
• Include outcomes stratified by sex and age when relevant.
• Report use of molecular risk calculators or nomograms.
• Describe dose adjustments for thyroid hormone suppression therapy.

JTC is committed to rigorous, transparent publishing in thyroid cancer research and care. We emphasize reproducible clinical methods, clear reporting of diagnostic criteria, and ethical compliance across all article types.

The editorial office supports authors, editors, and reviewers with clear guidance and responsive communication. For questions about scope or workflow, contact [email protected].

We encourage continuous improvement in reporting practices and share updates that help the community maintain high standards in endocrine oncology, surgical outcomes, and translational thyroid research.